At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Sunitinib Malate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients
In Brief
A Phase 2 clinical trial evaluating Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, and 1 other intervention for Childhood Cerebellar Anaplastic Astrocytoma and 10 related conditions. Completed, enrolled 30 participants across 96 sites in 3 countries.
Detailed Summary
This phase II trial studies how well sunitinib malate works in treating younger patients with recurrent, refractory, or progressive malignant glioma or ependymoma. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChildhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma
CountriesAustralia, Canada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartJan 2012
Primary CompletionDec 2013
Study CompletionMar 2014
TodayJul 2026
First PostedOct 31, 2011
Enrollment StartJan 1, 2012
Primary CompletionDec 1, 2013
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.7 years ago
Interventions
Diagnostic Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies
Sunitinib Malatedrug
Given PO